The worst appears to be over for Mylan and its EpiPen controversy.
It took a $465 million settlement with the U.S. Justice Department and a grilling from Congress for its chief executive officer to get there.
The drugmaker's shares rallied Monday following Friday's settlement with the Justice Department, resolving claims by Medicaid that Mylan overcharged the government health program for the allergy shot. That helped erase some of the stock's 26 percent slide since August, when lawmakers began asking why Mylan had raised the EpiPen's price sixfold since 2007, and whether it ripped off the government along the way. Meanwhile, the cost of the shots hasn't changed.